This site is intended for healthcare professionals
Responding to unmet needs for metastatic castration-resistant prostate cancer
mCRPC in focus

Podcast series: What’s new in mCRPC?

Read time: 30 mins
Last updated:16th Jan 2024
Published:8th Dec 2023

Episode 1: Can progress in mCRPC improve daily clinical practice?

It's great, not only that we have a new treatment, but perhaps even more important that we have a new target, which is prostate-specific membrane antigen (PSMA).
Professor Karim Fizazi

Professor Karim Fizazi and Dr Elena Castro discuss the clinical impact of the latest developments in metastatic castration-resistant prostate cancer (mCRPC) and patients’ perceptions.

Episode 2: Guidelines are for people not diseases: Improving implementation

Guidelines can actually tell us what we should do when data are available, and the level of evidence is actually provided in guidelines, but often there is no evidence.
Professor Karim Fizazi

Professor Karim Fizazi and Dr Elena Castro discuss the available guidelines for the treatment of metastatic castration-resistant prostate cancer (mCRPC), their limitations and what to do when drug approvals outpace the guidelines.

Episode 3: Changing treatment approaches for mCRPC: What’s the evidence?

There are many patients who do not receive chemo or who just don’t want to receive chemo. So it’s important to develop drugs for these patients.
Professor Karim Fizazi

Professor Karim Fizazi and Professor Silke Gillessen discuss the evidence for optimal use of both older and more recent treatments for mCRPC, and the role of next-generation sequencing.

Episode 4: Looking ahead: Treatment questions and emerging targets in mCRPC

We have to be smart to select the correct patients for immunotherapy in general.
Professor Silke Gillessen

Professors Karim Fizazi and Silke Gillessen discuss ongoing research in mCRPC, in-development treatments including immunotherapies, and emerging treatment targets.

Welcome: